🟢 Vivani Medical is trading 5.38% up in pre-market after narrower Q2 loss

Vivani Medical is trading 5.38% up in pre-market at $1.41 after August 13, 2026, second-quarter results showed a narrower $6.4 million net loss and quarterly EPS of negative $0.07, reportedly beating the $0.08 estimate.

• Dosing was completed for all 20 participants in the SLIM-1 Phase 1 NPM-139 semaglutide-implant trial; top-line data are expected in November 2026.
• Cash totaled $20.8 million at quarter-end.